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Endoplasmic reticulum stressHuman endogenous retroviruses (HERVs) constitute 5–8% of human genomic DNA and are replication
incompetent despite expression of individual HERV genes from different chromosomal loci depending on the
speciﬁc tissue. Several HERV genes have been detected as transcripts and proteins in the central nervous
system, frequently in the context of neuroinﬂammation. The HERV-W family has received substantial
attention in large part because of associations with diverse syndromes including multiple sclerosis (MS) and
several psychiatric disorders. A HERV-W-related retroelement, multiple sclerosis retrovirus (MSRV), has
been reported in MS patients to be both a biomarker as well as an effector of aberrant immune responses.
HERV-H and HERV-K have also been implicated in MS and other neurological diseases but await delineation
of their contributions to disease. The HERV-W envelope-encoded glycosylated protein, syncytin-1, is
encoded by chromosome 7q21 and exhibits increased glial expression within MS lesions. Overexpression of
syncytin-1 in glia induces endoplasmic reticulum stress leading to neuroinﬂammation and the induction of
free radicals, which damage proximate cells. Syncytin-1's receptor, ASCT1 is a neutral amino acid transporter
expressed on glia and is suppressed in white matter of MS patients. Of interest, antioxidants ameliorate
syncytin-1's neuropathogenic effects raising the possibility of using these agents as therapeutics for
neuroinﬂammatory diseases. Given the multiple insertion sites of HERV genes as complete and incomplete
open reading frames, together with their differing capacity to be expressed and the complexities of
individual HERVs as both disease markers and bioactive effectors, HERV biology is a compelling area for
understanding neuropathogenic mechanisms and developing new therapeutic strategies.Medical Research Centre 6-11,
+1 780 407 1938; fax: +1 780
.
er).
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
Multiple sclerosis (MS) is the prototypic neuroimmune disease,
deﬁned by neuroinﬂammation within the central nervous system
(CNS) accompanied by demyelination and axonal disruption [1]. Viral
proteins, in particular glycosylated retrovirus envelope proteins, are
potent inducers of inﬂammation with ensuing cell damage and death
[2]. Approximately 8% of the human genome is comprised of
retrovirus-like sequences (retroelements) [3,4], represented chieﬂy
by human endogenous retroviruses (HERVs), which originated
through germ-line infection by their exogenous ancestors during
primate evolution [5]. Abnormal virus-encoded protein expression
(usually glycosylated) has been associated with the unfolded protein
response (UPR), causing endoplasmic reticulum (ER) stress withpotential adverse outcomes depending on the cell type including
inﬂammation and apoptosis [6]. Herein we review MS pathogenesis
together with the different HERVs implicated in MS and their
associated disease mechanisms (Table 1).
1.1. Clinical and neuropathological features of MS
Multiple sclerosis (MS) is a common and progressive neurological
disease, deﬁned by several phenotypes (relapsing-remitting, primary
progressive and secondary progressive together with less common
variants such as Marberg's, Balo's and Devic's syndromes), which
affects over 1 million people world-wide, usually beginning in the
prime of life, ages 20–40 years, and is associatedwithmarked physical
and cognitive disabilities and shortened life span [7]. The recent
application of rigorous criteria for the diagnosis of MS has reﬁned the
inclusion criteria for clinical trials, which may improve the trial
outcomes [8]. The neuropathological changes accompanying MS are
diverse and have been characterized into four different subtypes [9].
Demyelination and inﬂammation are the cardinal features of MS and
involve the CNS at all levels. Accompanying inﬂammation and
Table 1
Evidence for role of HERVs in MS.
HERV Disease associations Speciﬁc action
HERV-H/F Multiple sclerosis in addition
to certain cancers
Expressed in MS patients particularly
in lymphocytes
HERV-W Multiple sclerosis and
schizophrenia
Expressed in white matter lesions in
MS patients, schizophrenia also reported
HERV- K Multiple sclerosis Disease marker
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perikaryal injury [10]. Lesions in relapsing-remitting MS patients are
usually found in white matter and are characterized by disruption of
the blood-brain barrier (BBB), local edema and demyelination, typical
of inﬂammatory processes [11]. Conversely, in primary-progressive
MS, inﬂammatory processes are less predominant but progression to
disability and brain atrophy may evolve faster [12]. Interest in the
mechanisms by which demyelination and inﬂammation-related
damage to axons and neurons occur [13] has been complemented
by neuroimaging studies that suggest that axonal injury accompanied
by cerebral atrophy (loss of tissue) constitute a major mechanism by
which physical disability progresses during MS [1,14].1.2. MS pathogenesis
The role of immunopathogenesis as an etiologic determinant of MS
is supported by the large-scale genetic studies showing linkages to
multiple immune genes, especially to the MHC Class II loci on
chromosome 6 [15,16] and MS neuropathology, which implicates
multiple cell types within the CNS together with immune activation
[17]. The current dogma deﬁning MS pathogenesis is that it is a T-cell-
driven autoimmune disorder, albeit with diverse phenotypes [1].
Nonetheless, MS clinical and neuropathological phenotypes are highly
variable depending on the population and geographic domain. Much
of the understanding of MS immunopathogenesis has been inﬂuenced
by the use of different animal models, especially experimental
autoimmune encephalomyelitis (EAE) [18]. Both innate and adaptive
immune mechanisms have been shown to participate in the
immunopathogenesis of MS [19] although adaptive immunity may
predominate early in disease, reﬂected by selective T and B cell
activation accompanying clinical relapses. Multiple groups have
demonstrated that enhanced MHC class II expression on myeloid
cells and accompanying innate immune activation are associated with
damaged myelin and failure of re-myelination [20]. Th1-associated
innate immunity is also activated throughout the different phases of
disease, as indicated by persistently increased cytokine and chemo-
kine production by macrophages, microglia and astrocytes [21], even
into the later or secondary progressive stages of disease [22]. Indeed,
modulation/polarization of macrophages by disease-modifying ther-
apies may be an important mechanism by which these compounds
exert their therapeutic effects [23]. The mechanisms underlying
demyelination and axonal damage remain uncertain although
inﬂammatory molecules including cytokines, chemokines, prosta-
glandins, reactive oxygen species and matrix metalloproteinases have
been demonstrated to contribute to demyelination and axonal/
neuronal injury associated with MS [14,24,25]. The molecules
mentioned above represent a complex cascade of signaling events
that originate with activation of lymphocytes, macrophages and
astrocytes [17]. Activation of these latter cell types results in the
release of soluble intercellular signaling molecules that subsequently
either feedback on the activated cells or alternatively, induces cellular
changes, usually through receptor-mediated mechanisms to cause
damage to myelin, oligodendrocytes, axons and perhaps neuronal cell
bodies [13,26,27]. Given the substantial role of innate immune
mechanisms in MS and the burgeoning recognition of its involvementin prototypic neurodegeneration (e.g., Alzheimer's disease, amyo-
trophic lateral sclerosis), the contribution of primary neurodegener-
ative mechanisms (oxidative stress, excitotoxicity, endoplasmic
reticulum stress, apoptosis and other programmed cell death path-
ways) to the development of MS-associated neurological disability
has gained greater importance in recent studies of MS pathogenesis
[28]. Indeed, the modest clinical beneﬁts of immunosuppressive and
immunomodulatory therapies have prompted investigators to re-
examine potential pathogenic mechanisms in MS with an increased
focus on regulation on neurodegenerative disease mechanisms [29].
Environmental factors including infectious agents, lifestyle (to-
bacco smoking) and nutritional (vitamin D depletion, dairy products)
factors might contribute to MS development and progression [30].
There is remarkable diversity in the evidence that indicates MS is
caused by conventional exogenous infectious agents (herpes viruses,
coronaviruses, Chlamydial infections, etc.) and in fact, the data are
highly controversial in this area (reviewed in [30,31]). There is also
abundant evidence to support the hypothesis that genetics has a
pivotal role in an individual's susceptibility to MS, perhaps in con-
junction with triggering factors such as viruses. Although MS is not
inherited in a Mendelian fashion, concordance rates of 26% in
homozygotic twins (3% in dizygotic twins) are typically seen,
suggesting substantial discordance (~70%) [32]. Nonetheless, family
members of MS patients inherit a higher risk of developing MS,
arguing for a genetic predisposition to this disease [33]. There is a
strong genetic association between MS in Caucasians with the HLA
class II DRB1*1501 allele, which is in linkage disequilibrium with
DRB5*0101. The latter allele might confer MS risk by selecting for
autoreactive CD4+ T cells, while the former is suppressed in EAE by
deleting autoreactive T cells in mice transgenic for both the alleles
[34]. To date no speciﬁc genomic locus has been linked deﬁnitively to
MS onset or progression although several chromosomal loci and
multiple polymorphisms have been associated with MS [35],
particularly among genes associated with immune mechanisms.
Two principal hypotheses link MS and infection: the “prevalence
hypothesis” states that the causative agent is more common in high
risk areas, whereas the “polio hypothesis” and by extension, the
“hygiene hypothesis” suggests that early infection induces protective
autoimmunity and delayed infection increases the risk of disease [36].
Thus, several infections in early life might protect against the
development of MS, which could explain whyMS is rare in developing
countries or lower socioeconomic groups [37]. Although various
infectious agents are linked to MS, their presence may simply provide
an appropriate environmental trigger for development of an autoim-
mune response directed against CNS antigens [38]. Application of
sophisticated biochemical and molecular tools has led to identiﬁca-
tion of several viruses that exhibit an association with MS, albeit no
pathogen has been accepted as the causal agent of MS. Studies related
to virus infections in MS are largely serological and demonstrated by
antibody titers against a particular virus, although it has not been
elucidated whether these antibodies are elevated in response to the
etiological agent, or through molecular mimicry [39]. Infections
contributing to increased MS clinical activity of supposedly viral
origin occur in the upper-respiratory tract, are self-limiting and mild,
but might include pathogens such as Chlamydia pneumoniae and
Mycoplasma pneumoniae [40]. Among viruses, epidemiological studies
favor Epstein–Barr virus (EBV) while neuropathological studies
support HHV-6, HERVs and perhaps coronaviruses [37]. EBV serology
correlates with the distribution and onset of MS. While most adults
have been infected with EBV, a proportion of children are EBV
seronegative [37]. Meta-analysis studies of EBV infections in MS
suggest that there is a role for EBV, particularly with a higher number
of patients showing antibodies to EBV nuclear antigen than EBV
seropositive controls but whether the oligoclonal IgG from MS brain
and cerebrospinal ﬂuid (CSF) is speciﬁc to EBV remains unknown
[41]. A large Danish study reported that MS risk increases soon after
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a conﬁrmed association between EBV infection in children and MS
[37]. Although HHV6 and EBV are ubiquitous viruses, seroconversion
happens usually before or during puberty into adult life, matching
epidemiological evidence for time of exposure to the infectious agent
causing MS [41]. Oligoclonal antibodies in CSF of some MS patients
were determined to target the EBV-encoded proteins BRRF2 and
EBNA-1 [42]. Further, EBV was found to infect B cells, and plasma cells
and in brains of MS where viral latent proteins were expressed [43]. A
T-cell-mediated immune response to EBV-infected cells leads to
damage of neurons and oligodendrocytes as a result of bystander
activation [37].
Due to the complex immunophenotype of MS, the immune
response to human herpes virus (HHV)-6 has been difﬁcult to predict;
concentrations of serum IgG to HHV-6 were higher in RR-MS than CP-
MS while HHV-6 DNA was often detected during relapse in 15% of MS
patients showing presence of viral DNA. Several cells, including
oligodendrocytes in MS brains showed the presence of HHV-6 antigen
or genome, but not exclusively associatedwithMS. Of interest, several
retroviral infections exhibit clinical and neuropathological pheno-
types that resemble MS including human T cell lymphotropic virus
(HTLV)-1-associatedmyelopathy and human immunodeﬁciency virus
(HIV)-associated leukoencephalopathy [44]. Unlike most convention-
al exogenous viruses, retroviruses are integrated into the host genome
and continue to exert (auto)-immune effects for years after infection,
often in the absence of substantial viral replication [45].
1.3. Human endogenous retroviruses (HERVs)
Retroviruses are RNA viruses deﬁned by their expression of
reverse transcriptase and best exempliﬁed by the exogenous retro-
viruses, HIV-1/2, HTLV-I/II, murine leukemia virus (MuLV) and Visna–
Maedi virus, an early animal (sheep) model for MS (Fig. 2) [46].
Human DNA contains ~3,100,000,000 bp comprising ~20,000–25,000
genes, with many RNAs that are non-protein encoding and of no
deﬁned function to date [47]. HERVs were ﬁrst discovered in normal
brain tissue as type C-related retroviruses in 1981 [48]. All humans
carry human endogenous retrovirus (HERV) sequences as an integral
part of their genomes, comprising almost 8.29% of the human genome
[49] and are likely vestiges of retroviral infections during evolution. At
some point during evolution, exogenous (infectious) progenitors of
HERVs inserted themselves into the cells of the germ line, where they
have been replicated along with the host's cellular genes following a
Mendelian pattern [4,5]. Integration of endogenous retroviruses into
the human germ line is thought to have occurred 2 to about 70million
years ago depending on the individual retrovirus andwere introduced
by mechanisms involving reverse transcription [3].
2. HERV classiﬁcation
The classiﬁcation of HERVs is based on the tRNA speciﬁcity of the
primer binding site by adding the one-letter code for the corresponding
amino acid to HERV, HERV-H, -T, -W, -K, etc. [50]. Other systems of
classiﬁcation based on sequence identity to known exogenous retro-
viruses and also to copy numbers [51,52] have also been used. To date,
31 HERV families have been identiﬁed and are named according to the
transfer RNA used to prime reverse transcription [53,54] (Fig. 1).
However, based on sequence homology, HERVs can be grouped into 80
distinct families [55]. Several members of the HERV-W and -H families
have been shown to encode intact envelope proteins and currently 18
full-length HERV env sequences have been deﬁned [54,56–58], of which
9 were detected in the brain [54].
Endogenous retroviruses are divided into twogroupsbasedupon the
presence or absence of LTRs and are classiﬁed as gamma (I)-, beta (II)-
and spuma (III)-retrovirus-like retroelements [53]. HERVs are divided
into two groups based upon the presence or absence of LTRs. ThosewithLTRs can be further divided based on infectivity. Infectious endogenized
retroelements found in lower species especially rodents and felids with
LTRs are retroviruses (e.g. FeLV, some MuLVs), while noninfectious
elements with LTRs are retrotransposons and those lacking LTRs are
called retroposons [59]. HERVs were discovered using low-stringency
screening of human genomic libraries [60], PCR by oligonucleotide
homology to viral primer binding sites [61] and during analyses of
humangene loci [62]. They are identiﬁed as retroviruses becauseof their
provirus-like structure containing LTRs ﬂanked by short direct repeats
and primer binding sites ﬂanking internal coding regions. Other retro-
elements that make up the genome include long interspersed repeat
sequences (LINES) that transpose due to inherent reverse transcription
activity and processed pseudogenes whose motion is dictated by
reverse transcription not encoded by the pseudogenes [63]. Of the
retroelements present in the human genome, HERVs are signiﬁcant in
terms of both health and disease.
While HERVs represent a substantial proportion of the human
genome little is known about their biological actions, in large part due
to the paucity of experimental reagents (complete sequence data and
antibodies) and the widely held (incorrect) assumption that HERVs
were ‘junk’ DNA. HERVs correspond to approximately 1500–2000
proviruses together with at least 20,000–40,000 copies of solitary
LTRs per genome. HERVs have been ampliﬁed during evolution by
repeated reintegration of reverse-transcribed mRNA into the DNA of
germ-line cells [64–66]. However, it is now clear that HERVs express
proteins [67], are capable of being immunogenic [68] and respond to
immune stimuli [69] but are probably not replication competent [70],
unlike their exogenous counterparts (e.g. HIV-1/2, HTLV-1/2). Of note,
some HERVs can infect human cells but do not replicate, likely due to
mutations in the pol and gag genes although these mutations do not
preclude reverse transcription, protein expression, and the release of
viral particles. Thus, HERVs are best regarded as complex host
retroelement genes with the capacity inﬂuence cellular functions and
perhaps survival.
HERV gene expression is assumed to be regulated by their
individual LTRs or proximate gene promoters. Varied levels of
expression and cell-type speciﬁcity of isolated HERV-LTRs in human
cell lines suggest that HERV-LTRs may be a valuable source of
transcriptional regulatory elements for the construction of targeted
retroviral expression vectors [71]. HERVs have been associated with a
range of disease processes including neoplasia, auto-immunity and
fetal malformations [72,73]. However, HERVs have also been found to
be expressed in healthy normal tissues, such as placenta where they
are assumed to exert beneﬁcial effects [57,74]. We showed that
induction of individual HERV expression is neural cell-type- and
stimulus-speciﬁc but more importantly, was associated with neuroin-
ﬂammation [69]. Other groups have shown that speciﬁc HERVs are
associated with select adaptive immune responses depending on the
individual HERV and disease context [75,76]. HERVs might play
several roles in neuropathogenesis: cytokine/host gene modulation
with neurotoxin production/release, molecular mimicry and inser-
tional mutagenesis [77–79].
Mobile genetic elements in various species are functionally
involved in development of placenta [80] and brain [81], etc.
Induction of several HERVs is reported in different cell types derived
from patients with various diseases; anti-HERV antibodies and
retroviral nucleic acid sequences are detected frequently in autoim-
mune diseases such as systemic lupus, MS and Type 1 diabetes
mellitus, depending on the individual study [75]. The HERV-K Gag
protein and transcript have been reported to be highly expressed in
teratocarcinoma and breast cancer cell lines [82,83], HERV-E in
prostate carcinoma [84], HERV-H in leukemia cell lines [85] and
HERV-W in brain tissue and CSF from MS [57] and schizophrenic
patients [86]. The identity of individual HERVs has been controversial
in some instances, in large part because of the variation in encoding
loci using different detection techniques [87,88].
Fig. 1. Retrovirus envelope phylogeny. Phylogenetic analysis of endogenous and exogenous retrovirus env sequences from 36 different clones. The sequences were aligned in Clustal
X and evolutionary distances were computed using the Poisson correction method. All positions containing gaps and missing data were eliminated from the data set. The
evolutionary history was inferred using neighbor-joining method. Sequences are represented by accession numbers and the group to which they belong.
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HERVgeneexpression is principally regulatedby their individual LTRs.
Cytokines such as TNF-α are known to regulate HERV expression in a
temporal and tissue-speciﬁc fashion [89,90]. Although most HERV
integration events are ancient, there are human-speciﬁc integrations for
HERV-K (HML-2, 113 and 115) that are relatively new (400,000–
250,000 years ago) and the full-length provirus and pre-integration site
alleles arepresent in thehumanpopulation [32]. There is also evidence for
the ability of HERVs to mediate genomic rearrangements during primate
evolution [3]. Comparison of sequences, particularly in the LTRs of certain
HERV families, provides insight into the length of time a particular genetic
sequence may have been present in the genome. Examples of the
nonfunctional viral sequences that may have arisen through several
incomplete duplications, recombination events and mutations acquiredduring primate evolution are HERV-H, HERV-F and HERV-K [3]. Themost
abundant expression of different HERVs is observed in placenta and
embryonic tissues and also in reproductive tissues or cells such as testes
[91] andoocytes [92]. ThebroadexpressionofHERVs inembryonic tissues
may be sufﬁcient for induction of immunological tolerance towards
HERV-encoded proteins. HERV proteins could inﬂuence feto-maternal
immunosuppression during pregnancy when expressed in the placenta
[93,94], particularly in the trophoblast cells [67,95]. Interestingly, other
immunogenic pregnancy-associated glycoproteins are expressed by the
placenta but their role(s) in autoimmunediseases remains uncertain [96].
2.2. HERVs and MS pathogenesis
While the cause of MS remains unknown, there is widespread
consensus that an infectious agent operating on a background of genetic
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not the exclusive cause of MS [32]. HERVs could play several roles inMS
pathogenesis but the most plausible (and contemporary) explanation
for the effects inMS is that they act predominantly as a host component
of thepathogenic cascadeof events underlyingMS (Table 2). A retroviral
etiology forMSwas postulated in the past when 70% ofMS patients had
cross-reactive antibodies to Human T lymphotropic virus (HTLV-1/2)
and human immunodeﬁciency virus (HIV) antigens [97] although
subsequently disproved, underlining the danger of relying on serology
for viral detection. Jocher and coworkers found no HTLV-1 sequences in
peripheral bloodmononuclear cells (PBMCs) orMSbrain tissues [41]. As
it is now generally accepted that the genetic background of the host
plays a crucial role in the disease susceptibility and phenotype but
speciﬁc haplotypes of HERVsmight also predispose an individual toMS.
Evidence exists for polymorphisms in HERV-H env alleles at 2q24.3,
which interestingly is also the locus for substitutions in 50% of Swedish
blood donors [98]. HERV-R (ERV-3), whose allele is homozygous in
about 1% of the Caucasian population, exhibits polymorphisms
including deletions in the envelope protein [99]. In addition, the
HERV-W envelope sequence also shows molecular diversity in blood
that is dependent of the speciﬁc chromosomal locus [100].
A full-length copy of the HERV-W genome is located on
chromosome 7q21 [101] and the HERV-W7q envelope-encoded
protein, termed syncytin-1, was shown to be expressed in astrocytes,
perivascular macrophages and activated parenchymal microglia, in
acute and chronic demyelinated lesions [102]. Indeed, syncytin-1
overexpression in astrocytes resulted in cytokine and reactive oxygen
species production with ensuing in vitro and in vivo oligodendrocyte
injury. Importantly, given the abundance of syncytin-1 encoding RNA
and protein in controls and MS patients and its inability to replicate
despite the release of HERV-W genome and proteins from cells, it is
unlikely to behave like a conventional exogenous retrovirus but rather
serves as a modulator of disease. What factors govern syncytin-1
expression in neural cells remain uncertain although recent studies
suggest that epigenomic determinants such as DNA methylation are
unlikely to contribute to its induction [103].
The MS-associated retrovirus (MSRV) is also a member of the
HERV-W family [104] and indeed, the two retroelements share
approximately 88% identity within their envelope sequences. Previous
studies have shown, using degenerate PCR primers, that the MSRV pol
is also upregulated in neuroinﬂammatory conditions [69] but its DNA
copy number does not differ between MS and age-/sex-matched
controls [105]. Indeed, the MSRV pol is also upregulated in other
neurological disorders [72,106]. It has been reported that MSRV is
replication competent and behaves like an exogenous retrovirus,
which has prompted substantial interest aboutMSRV [107], especially
with recent data generated using MSRV envelope-speciﬁc PCR
primers that did not demonstrate up-regulation of MSRV in MS brains
[108,109]. It is now clear that there are multiple HERV-W members,
which vary in their sequence and chromosomal loci. Recent work also
indicates that among 7 individual HERV envelopes examined, only
syncytin-1 is upregulated in MS brain [102,108], underscoring theTable 2
Mechanism of action of HERVs in MS.
HERV Disease
pathogenesis
Mechanisms
HERV-W/Syncytin/
MSRV
Up regulated in
MS lesions
Induction of free radicals, ER stress and
subsequent oligodendrocyte death;
triggers toll-like receptor (TLR)-4 affecting
innate and autoimmunity
HERV-H Up regulated in
lymphocytes of
MS patients
Induction of antibodies against HERV;
induces cell-mediated immune response
to gag and env peptides; retrovirus-like
particles (RVLPs) observed in cultured
patient cellsspeciﬁcity of perturbed syncytin-1 expression in MS but the speciﬁc
syncytin-1 sequence (or encoding locus) predominating in the CNS
remains unknown. Indeed, these ﬁndings were conﬁrmed with
quantitative PCR analyses wherein syncytin-1 RNA and proviral
copy numbers were increased in brains of MS patients although we
did not ﬁnd differences in PBMCs, plasma or CSF fromMS and non-MS
patients [108]. Other human retroelements have also been posited to
participate in MS pathogenesis but a full understanding of their
pathogenic role(s) and underlying mechanisms remains to be deﬁned
[107]. HERVs potentially might act also as either genetic markers for
polymorphisms related to MS, or as markers of environmental/
endogenous stress [110,111]. Induction of HERV-H/RGH, HERV-W and
ERV-9 expression was reported when speciﬁc cell types (chieﬂy B
cells) from MS patients were cultivated in vitro [112]. Several studies
suggest that speciﬁc HERVs that occur in few copies in the genome
(e.g. ERV-3, HERV-R and HRES-1) may show polymorphic patterns in
MS andmight act as auto-, super- or neoantigens with the potential to
enhance inﬂammatory responses or induce autoimmune reac-
tions [110,113]. RNA encoded by these HERVs has been detected by
reverse transcriptase polymerase chain reaction (RT-PCR) with
degenerate primers in sera/plasma and brain tissues from MS
patients, although not exclusively from this patient group [107].
Other methods employed for detecting evidence HERVs in MS and
other diseases include electron microscopic identiﬁcation of ‘virus-
like’ particles, reverse transcriptase activity and autoantibodies in
blood and CSF, albeit with limited speciﬁcity or sensitivity [114].3. MSRV and its role in MS
Among HERVs associated with MS, MSRV has been the most
intensely studied. Leptomeningeal cells (LM7) isolated from the CSF
of MS patients, as well as monocytes and EBV-transformed B cells,
yielded a novel retroelement that was subsequently identiﬁed and
characterized as MSRV [104]. Along with a French group who
discovered MSRV in MS patients, particles containing reverse
transcriptase activity were also reported by a Danish group [58].
MSRV and HERV-H particles and RNA were found to be increased in
MS patients relative to controls [32,115,116]. However, it is possible
that several HERV loci contribute to and are activated in MS since
patients exhibit heterogeneous sequences. A pan-retro RT-PCR that
ampliﬁed a conserved pol sequence among all retroviruses was used
[104]. Using MSRV probes obtained from virion-associated RNA, a
novel HERV family was identiﬁed that is different from ERV9 and
genetically related to MSRV sequences and was named HERV-W
[57,117]. There is substantial controversy as to whether MSRV is an
endogenous or exogenous virus [118]. MSRV belongs to the ERV9
family of endogenous retroviruses (ERVs), and partial molecular
characterization revealed that MSRV has 75% homology to ERV9 [104].
Recent evidence points to MSRV being transcribed from HERV-W loci
on chromosomes 3q23, Xq22.3, 15q21.3 and recombinations between
loci on chromosomes 3p12.3 and 18q21.32, Xq22.3 and 5p12 [100].
Thus, MSRV is most likely transcribed from an endogenous element,
perhaps from truncated or HERV-W pseudogenes, driven by uniden-
tiﬁed promoters located upstream of these pseudogenes [100].
MS patients whose serum and CSF samples show detectable levels
of MSRV range from 50% in the French population [118] to 100% in
Sardinia [119]. It was also detected in blood from control groups
without MS (6%) [118], some bipolar disorder patients, 40% of other
neurological diseases [120] and in synovial ﬂuid from rheumatoid
arthritis patients (22%) [121]. Using primers speciﬁc to ERV9/MSRV,
although less sensitive than MSRV-speciﬁc primers [104], a cohort of
South African MS patients did not show the presence of MSRV, except
for one pregnant individual [122]. This could be attributed to the
degenerate primers used that might have ampliﬁed HERVs normally
expressed highly in the placenta.
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MSRV copy number inMS bloodDNA [123] are associatedwith a poorer
MS prognosis [124]. MSRV is also induced by inﬂammatory agents
[125,126] andmight also induce a potent inﬂammatory response [127].
This is particularly evident when none of the MS patients treated with
anti-inﬂammatory drugs showed detectable levels of MSRV [118]. Of
particular interest was the ﬁnding that IFN-β treatment reduced MSRV
load inplasmaandMSprogression index amongpatients examined for a
year [128]. It is also plausible that MSRV expression is activated in
response to certain inﬂammatory products or infectious agents,
particularly viruses (HSV-1, inﬂuenza virus). In fact the expression of
MSRV was enhanced in the presence of HHV-6 in MS patients [90]. The
pol and env genes of MSRV and their expressed proteins have also been
shown to be involved in inﬂammatory responses [129]. Gliotoxins
secreted from macrophages expressing MSRV also caused the death of
oligodendrocytes, key cells involved in the myelination process [130].
This ﬁnding might suggest a direct inﬂammatory role for MSRV gene
products. The pathogenicity of MSRV retroviral particles was evaluated
in severe combined immunodeﬁciency (SCID)mice graftedwith human
lymphocytes and injected intraperitoneally with MSRV virion. MSRV-
injected mice displayed cerebral hemorrhage and died within 5 to
10 days post injection. RT-PCR analyses showed circulating MSRV RNA
in serum for mice, with overexpression of TNF-α and IFN-γ in spleen
[131]. This in vivo study implies that MSRV retroviral particles fromMS
cultures might have potent immunopathogenic properties mediated by
T cells corroborating previously reported superantigen activity ofHERVs
in vitro, which appear to be mediated by overexpression of pro-
inﬂammatory cytokines [132]. The pathogenesis of MSRV could also
involve an innate immune response to the virus through toll-like
receptors (TLRs), whichwas demonstrated by the stimulation of PBMCs
with puriﬁed Env protein that resulted in the release of cytokines [127].
However, a subsequent study using a different approach could not
demonstrate an immune response to MSRV [114]. In the latter study, a
cohort of HLA-B7+-matchedMS (n=24) and healthy controls (n=29)
patients did not exhibit any cellular immune response to MSRV/HERV-
W. Further, serum and CSF from MS (n=50) and healthy controls
(n=29) did not exhibit antibodies against MSRV/HERV-W [114].
Several possible reasons might explain this phenomenon, including a
lack of antigens in the cohort studied, insufﬁciently sensitive method-
ology or lack of an immune response to the antigen [114].
3.1. ERVWE1/syncytin-1
The HERV-W envelope-encoded glycoprotein, syncytin-1, is readily
detected in healthy placenta and is principally expressed by the
chromosomal locus, 7q21.2 although there are other loci that encode
partial and complete sequences (Fig. 2). Syncytin-1 is also detected as
both transcript and protein in brain tissues from MS patients [102],
especially in astrocytes and microglia within active and chronic MS
demyelinating lesions [102]. Syncytin-1 appears to be distinct from
MSRV env, but with sequence similarities [100]. Syncytin-1 is over-
expressed in brainsof individualswithMS [102,133] and examinationof
its copy numbers by PCR techniques revealed a signiﬁcant increase in
RNA and DNA copy numbers in the brain tissue but not in peripheral
blood mononuclear cells, CSF or plasma of MS patients relative to
controls [108,134]. A major difference between syncytin-1 and MSRV
env is the localization of the protein. While the former is found
intracellularly and on the plasma membrane, MSRV has been reported
to be found as an extracellular virus, visualized by electron microscopy,
sedimenting at retrovirus buoyant density, with reverse transcriptase
activity and a poly A(+) RNA containing terminal repeats, gag, pol and
env sequences. However, aside from point mutations that distinguish
MSRV env from syncytin-1 [108], the MSRV env can also be dis-
tinguished from syncytin-1 by the presence of a 12 nucleotide insertion
in the cytoplasmic tail of the transmembrane region of MSRV. Using
speciﬁc probes, quantiﬁcation of DNA, RNA of MSRV and syncytin-1 inPBMCs revealed that MSRV was signiﬁcantly increased in PBMCs of MS
patients compared to controls in contrast to syncytin-1 [109].While the
expression of syncytin-1 in PBMCs in this study agrees with an earlier
study using a less sensitive PCR approach [108], the expression pattern
of MSRV env is at odds with other studies [100,108]. Interestingly,
syncytin-1-negative/ MSRV env-positive PBMCs from MS patients
showed MSRV Env glycoprotein expression, albeit with an antibody
that doesnotdistinguishbetweenMSRV env and syncytin-1 [100]. Itwill
be essential to raise antibodies against the 12-nucleotide insertion to
distinguish the two at the protein level. Whether the expression of
MSRV Env protein in PBMCs corroborates with its expression in the
brain is yet to be demonstrated. Nevertheless, these studies imply that
an assay to quantitatively determineHERV-Wviral load in plasma could
be developed as a prognostic tool for MS.
MS patients demonstrate enhanced syncytin-1 protein levels
particularly in astrocytes where its expression leads to induction of
several ER stress chaperones [135]. One of these chaperones is the old
astrocyte-speciﬁcally induced substance (OASIS), which enhances the
expression of inducible nitric oxide synthase (iNOS). Expression of iNOS
has been demonstrated inMS lesions, especiallywithin astrocytes and is
a keypathogenic feature ofMS [136]. Increased syncytin-1 expression in
astrocytes leads to inductionof free radicals [102]. Themyelinproducing
cells of the CNS, oligodendrocytes, are particularly vulnerable to free
radical mediated damage because the level of antioxidants might be
lower in this cell type [137]. Loss of oligodendrocytes and myelin
formation was demonstrated in mouse models of demyelination [102].
Implanting TNF-α in the corpus callosum of syncytin-1 transgenic mice
not only resulted in ER stress but also revealed loss of themyelin protein
CNPase and oligodendrocytes [135].
Several viruses such as herpes simplex virus [138], inﬂuenza virus
[139] and cytokines such as TNF-α [133] are capable of inducing
syncytin-1 expression. This HERV envelope glycoprotein might be
misfolded in the endoplasmic reticulum (ER) since it is capable of
inducing the chaperones whose main function is to correct misfolded
proteins and achieve cellular homeostasis. Retroviruses have been
shown to induce an ER stress response; the envelope protein of MuLV
is known to upregulate GRP78/BiP as a means to protect cells from
apoptosis [140]. However, when ER stress is prolonged, some of the
chaperones persist and bind to promoter elements resulting in
transcription of genes that alter cellular function. Astrocytes that
undergo ER stress as a consequence of syncytin-1 expression release
free radicals through the induction of iNOS mediated by OASIS. Free
radicals are responsible for much of the pathology in MS as evidenced
by axonal damage as well as death and damage of oligodendrocytes.
Blocking iNOS using inhibitors or scavenging free radicals using
ingredients found in many natural compounds (e.g., ferulic acid)
suppressed syncytin-1-mediated damage in cultured neural cells as
well as in amousemodel [102]. It could be argued that inhibiting iNOS
is not necessarily going to diminish lesions from developing in MS as
iNOS as free radicals also have trophic effects in addition to their
pathogenic properties [141]. Importantly, syncytin-1 overexpression
is restricted to the brain parenchyma in MS patients, which precludes
its usefulness as a clinical biomarker [108,134,142].
3.2. HERV-W and its receptors
While exogenous retroviruses enter somatic cells by binding to
their cognate receptor (s), HERVs reside within the genome and are
inherited in a Mendelian fashion. However, HERV proteins, particu-
larly syncytin-1, are known to bind cell surface proteins such as ASCT1
and -2, which are neutral amino acid transporters [143]. The syncytin-
1 protein has also retained the ability to interact with the receptor for
D-type retroviruses [67,143] and can confer infectivity to pseudo-
typed retroviral particles [144]. A widely dispersed interference group
of retroviruses that includes the feline endogenous virus (RD114),
baboon endogenous virus, HERV-W and type D primate retroviruses
Fig. 2. Diversity within syncytin-1. (A) Multiple sites of syncytin-1 integration (indicated by arrowheads) located throughout the human genome were identiﬁed by performing a
BLAT search with the syncytin-1 ORF from GenBank accession no. NM_014590 using the Ensembl human genome browser (www.ensembl.org). The genomic location of the original
syncytin-1 locus on chromosome 7 is indicated by a box. (B) Phylogenetic rooted tree showing sequence diversity within syncytin-1 depending the chromosomal locus (chr#
positions). Original syncytin-1 sequence (ERVWE1) is designated as syncytin-ORF chr7 NM 014590. The 10 homologous genomic regions with the highest BLAT scores over the entire
length of the syncytin-1 ORF were extracted and aligned using ClustalW, including sequences from syncytin-1 and the HERV-K envelope ORF, as an outgroup (GenBank accession no.
X82272). (C) Sequence heterogeneity within syncytin-1 in the vicinity of position 1099; a representative portion of an alignment of the 15 homologous genomic regions with the
highest BLAT scores, including sequences truncated relative to the syncytin-1 ORF. A high level of sequence similarity in several regions allows the design of cDNA synthesis primers
(red box) that will hybridize with syncytin-1-related mRNA sequences. Sequence divergence nearby will allow unambiguous identiﬁcation of individual transcripts in order to
determine the extent to which other syncytin-1-like transcripts are expressed.
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and 2 (hASCT1; gene name, SLC1A4 and hASCT2; gene name, SLC1A5)
as cell surface receptors. ASCT1 and -2 have been determined to be
putative receptors for syncytin-1 [143]; in fact, ASCT1 is predomi-
nantly expressed on brain astrocytes [145] and syncytin-1 engage-
ment of ASCT1 results in suppression of ASCT1 [146]. Viruses
pseudotyped with syncytin-1 were able to infect astrocytes and
macrophages but not neurons [135]. It remains plausible that some
HERVs still possess functions of infectious retroviruses that may have
been diverted by the host to its beneﬁt. In accordancewith a symbiotic
role for HERVs, it has been shown that syncytin-1 is a highly fusogenic
glycoprotein that is speciﬁcally expressed in the placenta and can
mediate cell–cell fusion ex vivo [147].
Retrovirus receptor interference or down-regulation proceeds from
direct interactions between the virus and the receptor or by indirect
(intracellular) mechanisms such as through redox-mediated regulation
of the receptor [148]. The receptors for syncytin-1, ASCT1 and 2, are
widely expressed on most cell types [143]. ASCT2 abundance is low inthe adult brain [149] and recent observations of ASCT2 immunostaining
in human brains represent the ﬁrst report of its expression predomi-
nantly in microglial cells [135]. In the mouse brain, ASCT1 was chieﬂy
expressed in GFAP-positive astrocytes in the cerebral cortex and corpus
callosum, but not in neurons, oligodendrocytes or activated/resting
microglia [150], similar to observations in the white matter of human
brains. Interestingly, weak ASCT1 labeling was observed around ER
cisterns, revealing its intracellular trafﬁcking pathway or ASCT1 may
have a functional role in exchange of ions between cytoplasm and ER
lumen [150]. ASCT1 was also found to be signiﬁcantly down-regulated
in glial cells treated with 7-ketocholestrol, a by-product of myelin,
damaged by oxidative stress, a key feature of MS [151]. Reduced
expression of ASCT1 in astrocytes from MS patients appears to have
adverse consequences for oligodendrocytes and perhaps other proxi-
mate cells' health and function. ASCT1 is the principal transport system
involved in the secretion of L-serine [152], a potent astrocyte-derived
neurotrophic factor [150], which is essential for myelination [153] and
neuronal survival [154]. Conversely, ASCT1 is also responsible for
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[154], preventing its extracellular accumulation. A reciprocal interaction
between syncytin-1 and its putative receptor, ASCT1, along with
diminished amino acid inﬂux has also been observed in the placenta
[155]. Down-regulation of ASCT1 expression in mouse brain capillaries
has been observed during the secondpostnatalweek and is speculated to
be due to lowered demand for small neutral amino acids from circulation
or their increased synthesis in local glial cells [150]. These results suggest
ahighly speciﬁc role forASCT1down-regulation, sinceanother astrocytic,
amino acid transporter, EAAT1 [156], was unaffected by syncytin-1
exposure [135]. Indeed, thisﬁnding supports earlier studies showing that
syncytin-1-mediated effects onoligodendrocyteswerenot dependent on
the glutamate receptors, NMDA-R or AMPA-R [102].
To investigate the mechanism underlying ASCT1 suppression in
astrocytes, it was hypothesized that nitric acid (NO)might play a role as
NOdonors are known tomodulate ASCT2 expression [157]. Further, the
rationale for using NO donors was that syncytin-1 mediates NO
production and formation of peroxynitrites [102], both of which are
known to induce ER stress [158]. Sodium nitroprusside (SNP), an NO
donor, diminished ASCT1 expression in astrocytes, but also induced
Egr1, a repressor protein of ASCT1 in neural cells [159,160]. Of note, Egr1
suppresses TNF-α [161], which may have pathogenic consequences in
MS due to the protective nature of this pro-inﬂammatory cytokine
[162]. Bcl-2-induced Egr1 DNA binding activity has been correlated to
oligodendrocyte death [163]. As iNOS and Egr1 are signiﬁcantly
enhanced in brain lesions of MS patients [164] with concurrent down-
regulation of ASCT1, there might be a potential role for Egr1 in MS
neuropathogenesis. A transgenic mouse model of MS was developed
that expressed syncytin-1 in astrocytes under the GFAP promoter.
Indeed, syncytin-1 transgenic mice exhibited neurobehavioral features
resemblingMS. T cell (CD3 immunopositive) inﬁltration into the corpus
callosum were observed in transgenic mice upon TNF-α implantation,
suggesting that the adaptive immune component of neuroinﬂammationFig. 3. Syncytin-1-mediated neuropathogenesis in multiple sclerosis. Inﬂammation induc
cytokines and free radicals together with altered transport of amino acids implicated in neu
astrocytes, which damage oligodendrocytes leading to demyelination and axonal injury.is activated in this model. When syncytin-1 was over expressed in
human astrocytes, syncytia develop [135], which recapitulates an
occasional ﬁnding of multinucleated (syncytia) astrocytes in plaques
from MS patients [165]. Engagement of ASCT1 by syncytin-1 or
treatment with IL-1β results in suppression of its expression although
the mechanism by which this reductionmight occur remains uncertain
[146]. Of interest, ASCT1 was also suppressed in the syncytin-1
transgenic mouse [135]. The down-regulation of ASCT1 in whitematter
of MS brains has important implications for oligodendrocyte and
neuronal survival, given that ASCT1 on astrocytes is responsible for the
export of L-serine, which can serve as a neurotrophic factor [154].
Astrocytes are the chief source of L-serine in the CNS [154] and the
principal cells type expressing ASCT1 [150]. L-serine biosynthesis plays
an important role inmultiple cellular reactions, particularly in the brain,
as L-serine is a precursor of important metabolites such as nucleotides,
phospholipids and the neurotransmitters, L-glycine and D-serine.
Disturbances of serine-glycine metabolism in relation to N-methyl-D-
aspartate-receptor activation might also play a role in MS pathogenesis
[166]. Interestingly, disruption of L-serine biosynthesis, through
deﬁciency in the enzyme, 3-phosphoglycerate dehydrogenase, results
in dysmyelination, seizures and psychomotor retardation [167]. Earlier
data indicated that treatment of astrocytes with the ASCT1 blocker,
benzylserine, mediated oligodendrocyte injury and death [135]. Indeed,
the underlyingmechanisms bywhich syncytin-1mediated its cytotoxic
effects appeared to involve activation of the unfolded protein response
(UPR) in the CNS, resulting in endoplasmic reticulum (ER) stress, which
can lead to inﬂammation and altered cell survival [168] (Fig. 3).
3.3. The unfolded protein response (UPR) and endoplasmic reticulum
(ER) stress
The endoplasmic reticulum has 3 basic functions: (1) protein
synthesis, (2) protein folding and (3) calcium storage [169,170].es expression of syncytin-1 in astrocytes (and microglia), resulting in the release of
ropathogenesis including L- and D-serine, cysteine due to altered ASCT1 expression on
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apparatus for protein trafﬁcking [170]. However, when the levels of
unfolded or misfolded proteins in the ER are too high for effective ER
function, four mechanisms of cellular response to this condition can
be activated, which are collectively termed the unfolded protein
response (UPR) [170]. The ﬁrst mechanism of the UPR is to increase
the expression of ER chaperones to increase the rate of correct
protein folding in the ER [170]. If this mechanism fails, the second
UPR mechanism is translation attenuation, which decreases the rate
at which proteins are synthesized in the ER and hence decreases the
rate at which proteins accumulate in the ER [170]. If these two
mechanisms are not successful, the third UPR mechanism is ER-
associated degradation (ERAD) [170,171]. During ERAD, proteins are
tagged and retrotranslocated out of the ER into the cytoplasm where
they are degraded via the ubiquitin–proteosome pathway [171].
However, if ERAD fails, unfolded proteins aggregate and lead to the
fourth and ﬁnal UPR mechanism: ER stress [170]. ER stress can lead
to apoptosis, oxidative stress and inﬂammation [170,172]. There
are 3 principal ER stress sensors: PERK (PRKR-like endoplasmic
reticulum kinase), IRE-1 (inositol requirement enzyme-1) and ATF-6
(activating transcription factor 6) [173,174] (Table 3). PERK is a
protein kinase that is activated when there is ER stress; its role in ER
stress is to phosphorylate eIF-2α and stop translation [169,175]. IRE-
1 has kinase and endoribonuclease activity; however, its cardinal
function in ER stress is to cleave a 26-bp intron in pre-mature
transcript of XBP-1 (X-box binding protein 1) [172,175]. The third ER
stress sensor, ATF6, is a transcription factor that has a basic region
and a leucine zipper motif and its principal role in ER stress is to
enhance transcription of ER chaperones [172,173]. In the absence
of ER stress these 3 ER stress sensors are bound to binding
immunogenic protein (BIP) and expressed at a very low level
[174]. The main control for these three sensors, BiP, is an ER glucose
regulated chaperone that plays a major role in ER stress [171–173].
Upon ER stress (caused by accumulation protein and failure of the
other 3 UPR mechanisms), BIP dissociates from the three ER stress
sensors and each of which activates its own unique set of pathways
[174] (Fig. 4).
Upon dissociation from BiP, PERK will phosphorylate eIF-2α to
attenuate translation, thus phosphorylating eIF-2α thereby inactivat-
ing it [172]. The alpha subunit of the eukaryotic translation initiation
factor (eIF-2α) is involved in the initiation of translation of proteins in
the ER [172]. Phosphorylated eIF-2α will enhance translation of
speciﬁc mRNA for transcription factors like ATF4 or chaperones such
as CHOP which will in turn activate the transcription of anti-oxidant
genes and stimulate the expression of ERAD component genes
[170,176]. NF-κB is a key transcriptional regulator and once in the
nucleus, it will activate transcription of several inﬂammatory genesTable 3
ER stress proteins and their essential functions (common names underlined).
ER stress protein Full name Other Alias Function
BiP Binding Immunoglobulin protein GRP78 Folding of g
proteins wh
ATF-6 Activating Transcription Factor 6 – Binds to ER
BiP. Activat
PERK PRKR-like Endoplasmic
Reticulum Kinase
WRS, HRI Phosphoryl
enhanced tr
IRE-1 Inositol Requirement Enzyme 1 DIRE-1 IRE1-alpha
converts XB
OASIS Old Astrocyte Speciﬁcally
Induced Substance
CREB3L1 Activates th
AMP-respon
CHOP C ⁄ EBP homologous protein GADD153 Apoptosis, g
GRP58 Glucose Regulated Protein PDIA3 Folding of n
CALR Calreticulin – Folding of g
CANX Calnexin MHC class 1 antigen
binding protein p88
Folding of g
XBP-1 X box binding protein 1 TREB5 Transcriptio[172]. IκB, an inhibitor of NF-κB, has a shorter half life than NF-κB, and
therefore, global attenuation of translation by eIF-2α phosphorylation
leads to NF-κB dissociation from Iκ-B and its translocation into the
nucleus where it is a key transcriptional regulator of inﬂammatory
genes [172]. The resulting increase in expression of ROS-producing
enzymes such as iNOS and an increase in cytokine production in
the CNS may contribute to neuropathology of neuroinﬂammation
[172,177].
When IRE-1, the second major ER stress sensor, dissociates from
BiP, it will cleave an intron in the pre-mature XBP-1 transcript and
yield a mature XBP-1 transcript [174]. XBP-1 is a transcriptional
regulator in ER stress and also plays a role in MHC class II regulation
[172,173,178]. XBP-1 will then translocate into the nucleus and
activate the transcription of ER chaperones [170]. IRE-1 can also
activate NF-κB when it forms a complex with TRAF2, which will be
discussed in the next section (24). The third main ER stress sensor,
ATF-6, is a transcription factor that gets cleaved by the proteases SP1
and SP2 and then translocates into the nucleus to activate transcrip-
tion of ER chaperone genes [174].
Recent studies indicate that ER stress is linked to inﬂammation,
speciﬁcally the systemic inﬂammatory component of innate immunity,
called the acute phase response [172]. Members of the membrane-
bound transcription factor family with homology to ATF6 include
CREBH, Luman and OASIS [179]. CREBH is a hepatocyte-speciﬁc bZip
transcription factor belonging to the cyclic AMP response element
binding protein transcription factor (CREB/ATF) family, which requires
proteolytic cleavage for its activation. Interestingly, pro-inﬂammatory
cytokines induce and cleave CREBH, which regulates C-reactive protein
(CRP) and serum amyloid P-component (SAP), which are implicated in
several pathologies [172] including MS, where levels of these proteins
are augmented in the serum [180]. CRP can bind to and activate
monocytes/macrophages [181], whereas SAP plays important roles in
leukocyte adhesion [182].
3.4. ER stress and viral diseases
Viral infections of mammalian cells elicit cellular responses, such
as ER stress and interferon responses [183]. Viruses have evolved
mechanisms to challenge these responses that limit/inhibit viral
replication. The ER is an essential organelle for viral replication and
maturation and in the course of a productive infection, a large amount
of viral proteins are synthesized in infected cells, where unfolded or
misfolded proteins activate the ER stress response [183]. Several viral
proteins trigger Grp78/BiP expression during infection, which in turn
associates transiently with folding intermediates of viral glycopro-
teins. This binding facilitates folding or assembly of viral proteins
along the maturation process [183]. Hepatitis C replication stimulateslycoprotein, separates from ATF-6, IRE-1 and PERK and binds to unfolded/misfolded
en ER stress is present.
stress response elements and activates the transcription of ER chaperones such as
ion of CHOP promoter.
ates eIF2a to attenuate translation, and to upregulate expression of ATF4, leading to
anscription of target genes such as CHOP.
and IRE1-beta undergo dimerization and transphosphorylation under ER stress and
P-1 pre-mRNA into XBP-1 mature mRNA
e transcription of target genes that are mediated by ER stress-responsive and cyclic
sive elements.
rowth arrest, oxidative stress, DNA damage.
ascent proteins.
lycoproteins. Not directly involved in ER stress.
lycoproteins.
n of ERAD components and ER chaperones. Activation of CHOP promoter
Fig. 4.Mammalian ER stress mechanisms. In the absence of ER stress, BiP is bound to all 3 ER stress cascade initiators (PERK, IRE1 and ATF6). When ER stress occurs, BiP dissociates
from the ER stress cascade initiators and binds to the unfolded and misfolded proteins. PERK is a kinase that phosphorylates EIF2α which leads to the translocation of ATF4 and
ultimately activation of CHOP promoter. Endonuclease, IRE1, splices XBP1 pre-mRNA into its mature transcript variant and also leads to the induction of CHOP. ATF6 is a transcription
factor that gets cleaved twice before it translocates into the nucleus to enhance the transcription of CHOP and ER chaperone genes. Also ER stress can indirectly lead to increased iNOS
and production of pro-inﬂammatory cytokines through oxidative stress.
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effect favors translation of viral proteins. There is an increased level of
Grp78/BiP, which may be stimulated by viral replication. Infection by
cytomegalovirus transiently induces Grp78/BiP at early stages but
returns to basal levels at the later stage. This coincides with
expression of other markers of UPR. Increased Grp78/BiP at the
early stages inhibits the stress response by interacting with PERK,
ATF6 and IRE1. Thus, the virus seems to induce Grp78/BiP in order to
control ER stress [183].
Caspase-12 is an initiator caspase required for transduction of a
death signal from the ER in infected cells and is activated by several
viruses and the onset occurs before activation of caspase-8 and -3 [185].
Multiple viruses induce apoptosis mediated by ER stress through the
activation of GADD153/CHOP. Virus infection activates the p38 MAPK
pathway, which then acts on GADD153/CHOP to initiate apoptosis in
infected cells. Through the regulation of as yet unidentiﬁed proteins,
several viruses including African swine fever virus, block the expression
of GADD153/CHOP [183]. It is unclear, however, why some viruses
promote ER-mediated apoptosis. Several studies of neurotropic murine
retroviruses have reported the induction of inﬂammation and ER stress-
related genes [186]. Moreover, ER stress was related speciﬁcally to an
individual envelope protein expressed by the retrovirus. A temperature
sensitive neurovirulent mutant (ts1) of Moloneymurine leukemia virus
(MoMuLV) [187] has a singlepointmutation in the envgene that confers
the ability to kill T cells and motor neurons, causing a progressive
spongiform encephalopathy [187]. Neurodegeneration is probably due
to loss of glial support and release of TNF-α, IL-1β andNO from adjacent
ts1-infected glial cells [187]. Neurons display apoptosis, vacuolization
and inclusion bodies. Elucidation of the pathogenic mechanisms hasrevealed a role for ER stress in neuronal death. TNF-α or NO induces the
ER to release Ca2+ leading to activation of ER stress signaling pathways
and cell death through apoptosis.
Infection by the neurovirulent murine retrovirus, MoMuLV ts1, is
associated with phosphorylation of PERK and eIF2α ([186]. During late
stages, levels of Grp78/Bipmay be insufﬁcient to protect neurons against
ER stress associated with neurovirulent murine retroviruses, FrCasBrE
and MoMuLV ts1 infection. Neurons, but not astrocytes, show increased
levels of ER stress associated genes in infected mice, which result in
activation of ER-associated caspase-12 and subsequent cleavage of
caspase-3. Stressed neurons also exhibit increases in [Ca2+]i-mediated
phosphorylation of calmodulin (CaM) kinase IIα. Since ts1 infects glial
cells, but not neurons, an indirectmechanism of neuronal death, perhaps
glutamate excitotoxicity associated with NMDA receptor activation due
toneurotoxins from infected glia,might lead toneurodegeneration [187].
The envelope protein of an avirulent retroviral strain, F43, binds to
Grp78/BiP and is processed through the normal secretory pathway. In
contrast, the envelope protein of FrCasBrE bound to Grp78/BiP for a
prolonged period is retained in the ER anddiverted to the proteasome for
degradation [186]. MoMuLV ts1-infected astrocytes induce GADD153/
CHOP in neurons but not astrocytes [187,188]. GADD153/CHOP and
Grp78/BiP as well as iNOS and apoptosis are induced in p53 deﬁcient
microglial cells when treated with lipopolysaccharide [189] or IFN-γ,
suggesting p53-independent NO-induced apoptotic mechanism in
microglia [190]. Both FrCasBrE and ts1 strains induce a proteinmisfolding
disease since Grp78/BiP binds to hydrophobic residues and attempts to
prevent protein aggregation of misfolded proteins and thus activating an
UPR. We have shown that replication-competent feline immunodeﬁ-
ciency virus (FIV) is essential for inducing an ER stress response and a
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vivo. However, mere exposure and/or expression of the envelope protein
of FIV were insufﬁcient to induce an ER stress response [191]. ER stress
can activate inﬂammation through activation of NF-κB, as previously
described. Similarly TRAF2 ((TNF-α)-receptor-associated factor 2) can
form a complex with IRE-1α and also activate inﬂammatory genes
through a phosphorylation cascade [172]. TNF-α is a cytokine that
breaches the BBB and causes neuroinﬂammation [172,192]. IRE-1α-
TRAF2 complex can phosphorylate JNK (JUN N-terminal kinase), which
phosphorylates AP1 (transcription factor activator protein 1) [172].
Similar to NF-κB, phosphorylated AP1 can translocate into the nucleus
and activate the transcription of inﬂammatory genes [172].
A recent study by Lin et al. [193] examined ER stress involvement
in demyelinating disorders. Interferon (IFN)-γ, a cytokine induced
during T cell activation, is potentially involved in demyelinating
disorders by causing oligodendrocytes (ODCs) to undergo apoptosis
[193]. Lin et al. [193] treated rat ODCs for 48 hours and examined their
viability with caspase activation and ER stress transcript levels. By
double labeling rat ODCs with CNPase and TUNEL, apoptosis can be
visualized speciﬁcally in ODCs. ODCs treated with IFN-γ for 48 hours
showed signiﬁcantly higher in double labeling (CNPase and TUNEL)
than untreated ODCs [193]. Caspase-3 activity assay in ODC lysates
was signiﬁcantly higher in ODCs treated with IFN-γ for 48 hours
compared to untreated ODCs [193]. Western blotting of the
phosphorylated form of eIF-2α derived from ODCs treated with IFN-
γ for 48 hours shows a more intense immunoreactive band than
untreated ODCs when compared to the western blot of unpho-
sphorylated form of eIF-2α [193]. Also in the same study, rat ODCs
treated with IFN-γ for 48 hours had increased BiP, CHOP (GADD153)
and caspase-12 relative transcript level compared to untreated ODCs
[193]. These ﬁndings suggest ER stress may have a role in IFN-γ
induced ODC apoptosis. IFN-γ- induced ODC apoptosis is likely
relevant in the pathogenesis of neuroinﬂammation [192].
3.5. Other HERVs of relevance to MS pathogenesis
3.5.1. HERV-H
HERV-H has also been studied in MS patients, particularly in
Scandinavian populations [107]. The in vitro production of retrovirus-
like particles (RVLPs) in cell cultures fromMS patients but not healthy
controls may be enhanced or activated by infectious triggers such as
Herpes viruses (e.g. herpes simplex virus (HSV), EBV). Independent
molecular analysis of retroviral RNA associatedwith RVP revealed two
different genetic families of endogenous retroviral elements: MSRV/
HERV-W and RGH/HERV-H. Retroviral particles of the latter were
reported to be transmitted to mitogen-stimulated lymphocytes from
healthy donors [115,116]. Although this study was not conﬁrmed, it
suggests that one or more HERVs may be associated with MS. In a
recent study from Spain, of 48 MS patients studied within a patient
population of 92, CSF samples showed no HERV-H RNA [194]. In fact,
HERV-W was also not detected. In a Danish study, using a well-
controlled study group, seroreactivity to select HERV-H peptides was
determined by a sensitive time resolved immunoﬂuorometric assay
and generallyMS patients with an active disease status had antibodies
to several HERV-H peptides compared to non-active disease as well as
unaffected relatives. At least 50% of the MS patient sera exhibited this
response and there was a positive correlation with lower levels of an
innate immune molecule, MASP3 [195]. In agreement with other
infectious agents associated with MS, HERV-H was found to show a
profound increase in cell-mediated immune response when peptides
corresponding to the gag and env regions elicited a signiﬁcant
proliferative effect when combined with HSV and HHV-6A [32].
Indeed, splice variants of HERV-H envwere also detected in about 40%
of MS patients and attributed to the high transcription and translation
of HERV-H env-encoded protein, which also elicited a strong
serological activity. Interestingly, the splice variants associated withMS did not have any known homology with a host gene and thus
ascribing loci was not achieved [116]. Most studies with HERV-H have
involved determining whether there is a serological response to
HERV-H antigenic peptides and invariably MS patient-derived PBMCs
(which are in an activated state) always respond to these peptides
more vigorously than control-derived PBMCs [196]. T cells and PBMCs
from 25% of MS patients when cultured express retrovirus-like
particles, which vary in size from 70 to 100 nm and appear mor-
phologically similar to type C retroviruses in being irregularly
rounded, with surface projections on the envelope and a relatively
electron dense nucleocapsid/core [107]. Retrovirus-like particles
(RVLPs) isolated by both the Danish and French groups from MS
patient lymphocyte cell lines were examined by electron microscopy;
large numbers of RVLPs were noted in the cytoplasm in case of MSRV,
and these were not observed with HERV-H, in addition to differences
in core density, particle size and morphology [107].
Due to the apparent ubiquitous presence of several exogenous
viruses in MS patient tissues, synergism between some of these
viruses and HERVs were examined in various studies. Using the
sensitive PERT assay, Brudek et al. [197] examined reverse transcrip-
tase in MS patient lymphocytes and determined that UV-inactivated
HSV-1, HHV-6A and VZV could induce HERV reverse transcriptase
activity in PBMCs, suggesting that viral proteins are sufﬁcient to
induce reverse transcriptase activity and a productive infection is not
necessary [197]. In a follow up study, the same group examined the
synergism between herpesvirus antigens and HERVs in the release of
pro-inﬂammatory cytokines in PBMCs [198]. Assuming that HERV-H
was the retrovirus used for the assay due to their long standing
interest in the same, RVLPs were isolated from a B lymphoblastoid cell
culture. While HERV-H alone did not induce cytokine production or
cell proliferation but in combination with herpesvirus (HSV, VZV),
there was a signiﬁcant increase in IFN-γ, a pro-inﬂammatory cytokine
which is known to exacerbate disease. HHV-6A also induced reverse
transcriptase activity as well as a proliferative response [198]; it did
not induce cytokines in the latter study [198]. This could be attributed
to a different cohort of patients or other aspects of the study. Since
nearly 100% of the Danish population is seropositive for HHV-6A and
VZV, the role of HERV-H might be stronger than one might have
anticipated, due to polymorphisms in the env gene of HERV-H.
3.5.2. HERV-K
An allelic variant member of the HERV-K family, K18, was recently
found to be a risk factor for MS [111]. Although the small sample size
was a limitation, there was a signiﬁcant association between HERV-
K18 env genotype and risk of MS [111]. HERV-K18 env has previously
been described as a superantigen transactivated by EBV in the
pathogenesis of type 1 diabetes [75]. Another member of the HERV-K
family, K113, with ORFs for all its genes, has a widespread geographic
as well as ethnic variation in 0–28% of humans, increasing the
possibility of its association with MS since the disease is perhaps
geographically and ethnically restricted. However, using a large
population of MS (n=951) and unaffected parents (n=1902),
there was no signiﬁcant increase in the HERV-K113 provirus allele
by PCR analysis [199]. Thus, while K18 shows association in a small
subset of MS patients, a larger study with another HERV-K member,
K113, reveals no signiﬁcant differences; disparities in both the
number of patients examined and the HERV-K genotype make this
association inconclusive.
HERV-K is a relatively new HERV and was present in allelic form in
15% (115 HML-2) to 30% (113 HML-2) in DNA of known and unknown
ethnic origins. Although no clear association of a HERV haplotype with
host genotype has been made to date in MS patients, there is some
evidence that depending on the population, the LTR sequences of
HERVs such as HRES-1 show polymorphisms within MS patient
haplotypes while those from non-MS patients were identical without
geographic restrictions [110].
Table 4
MS drugs potentially effecting HERV expression.
Drug Example Drug's principal mode of action Action against HERVs
Immunomodulatory agents Interferon-β Decreases leukocyte transmigration;
antiviral;
Reduces HERV-W env RNA load, anti-HERV-W and HERV-H antibodies in sera;
regulates syncytin promoter
Anti-psychotics Reduction in intensity, density and compound value of HERV-W gag interneurons
in alveus of patients with schizophrenia (Weiss et al., 2007)
Antiviral Foscarnet Inhibits reverse transcriptase Blocks endogenous retrovirus (Sundquist and Oberg, 1979)
173J.M. Antony et al. / Biochimica et Biophysica Acta 1812 (2011) 162–1763.5.3. Conclusions and future directions
Given the diversity of ﬁndings related to HERV expression with
several conﬂicting reports, there are issues requiring further attention in
this ﬁeld including standardization of procedures for detecting and
deﬁning different human retroelements. Moreover, these types of
studies need to be extended to different populations in which MS is
common together with analyses of HERV molecular diversity. It is
conceivable that HERV allelic variants exert speciﬁc effects on the MS
phenotype, progression and response to therapy depending on the host
genetic background. Indeed, detection of sequences will require
conﬁrmatory sequencing to establish the encoding locus before
deﬁnitive associations between disease and speciﬁc HERVs can be
made. For example, it is imperative to understand themolecular nature
of HERV recombination events that might trigger the emergence of a
novel retroelement from individuals with MS, its geographic restriction
andepidemiological features. In addition, allelic variationwithin speciﬁc
HERVs, already associated with disease, warrants investigation. Since
detection of MSRV, syncytin-1 and HERV-H in serum, plasma and brain
tissue have depended on the use of RT-PCR, the use and efﬁcacy of this
technique for quantiﬁcation of multicopy genes such as HERVs has
recently raised questions about its utility. Quantitative RT-PCR analysis
has not been performed in many studies, largely because of the large
number of truncated HERV genes in the genome, pseudogenes and the
homology between members of the same family. In addition to probes
which distinguish HERVs, stringent PCR analyses that conform to
standard conditions should be implemented [142].
Production of pathogenic (inﬂammatory or death signaling)
molecules has been associated with retroviral expression [130],
especially the envelope protein [2]. It has been postulated that there
may exist a pathogenic cascade in MS involving several step-speciﬁc
pathogens interacting with particular genetic elements leading to
enhanced retroviral expression [200]. There is no conclusive proof
that any HERV plays a major role in human disease although
investigators have postulated several possible pathogenic mechan-
isms. HERVs, for example, could enhance the transcription of cellular
genes downstream of HERV-LTRs that contain promoter elements.
HERVs have also been posited to encode superantigens that result in
enhanced inﬂammatory responses or mimic self-antigens leading to
autoimmune pathologies such as lupus or MS [201]. Viral proteins
interact directly or indirectly with promoters of various inﬂammatory
cytokines and regulate their expression in infected cells. MSRV can be
transactivated in vitro by two herpes simplex virus type 1 immediate
early proteins [202] and thus act as triggering cofactors of MSRV in the
pathogenesis of MS. In a similar fashion, MS long-term lymphocyte
cell lines, which are EBV-transformed B cells with a T cell sub-
population, with high reverse transcriptase activity attributed to
HERV-H RVLP, also produced signiﬁcant levels of IL-2, IFN-γ, GM-CSF
and TNF-α [107]. However, MSRV showed a different cytokine proﬁle
with patient lymphocytes and with no correlation to RT activity [130].
In fact, cytokines such as IL-4, IL-6, TNF-α and IFN-γmight induce the
release of MSRV particles thereby contributing to the pathogenic
feedback loop [125]. These differences in cytokine proﬁles are to be
expected as MS is a heterogeneous disease and compounded by allelic
variations among patients, multiple cellular constituents (lympho-
cyte, PBMC, brains, CSF), stage of the disease, treatment regimen, etc.
However, in a recent new study, MSRV env, MSRV gag and syncytin-1did not provoke immune responses among MS patients who were
HLA-B7 matched [114]. This observation suggests that either some
speciﬁc antigenic epitope among the RVLPs is necessary or a speciﬁc
protein folding pattern which might not be achieved in insect cells
when recombinantly produced or that the pathogenesis is localized to
the CNS as argued for syncytin-1 [102,134,135].
Syncytin-1 expression is enhancedbyvarious viruses includingHSV-
1 infection [138]. Yet induced expression of several HERV genes is
observed in neuroinﬂammatory diseases including MS [69], suggesting
that HERVs found in MS are a by-product of the inﬂammatory
component of MS, diluting the contention of some researchers that
HERVs are a causative pathogenofMS [201]. AlthoughHERVs arenot the
apriori cause ofMS, theymightparticipate in thepathogenesis suchas in
ER stress, and hence blockingHERV function in the CNS through speciﬁc
therapies might diminish the progression of MS. While HERVs might
also act as auto-, super- or neoantigens (upon expression of oncogenic
viruses), HERV variants could participate in antigenic mimicry, all of
which have the potential to enhance inﬂammatory responses or induce
autoimmune reactions [110]. However, HERV-W expression in schizo-
phrenia in which there is a lack of inﬂammation does not support this
hypothesis. HERVs are present at conception in humans and if the genes
are involved in pathogenesis through polymorphisms or reintegration,
there should be apredominanthereditary component of the disease and
aminor environmental role. This is not the casewithMS,which exhibits
signiﬁcant hereditary and environmental susceptibility factors. Our
understanding of HERVs is limited due to variability in the composition
of humanDNA in termsof copynumber variations, deletions, expression
patterns associated with methylation and tissue-speciﬁc effects. Given
the abundance of HERV sequences in the human genome (complete or
incompleteORFs), it is also conceivable that retroelements express non-
coding RNAs that act as microRNAs or siRNAs [203]. Because HERVs
are conserved evolutionarily, differentially expressed in speciﬁc tissues
and might participate in disease inheritance, susceptibility and
progression, it is imperative to delineate HERV genetics and biology.
Indeed, elucidation of individual HERV contributions to pathogenesis
might enhance treatments for MS (Table 4) and other diseases that
involve HERV expression or activation in a patient- or population-
speciﬁc manner.
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